Arcticzymes Technologies ASA (OL:AZT) — Market Cap & Net Worth
Market Cap & Net Worth: Arcticzymes Technologies ASA (AZT)
Arcticzymes Technologies ASA (OL:AZT) has a market capitalization of $110.71 Million (Nkr1.05 Billion) as of September 17, 2026. Listed on the OL stock exchange, this Norway-based company holds position #18891 globally and #168 in its home market, demonstrating a -2.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arcticzymes Technologies ASA's stock price Nkr20.60 by its total outstanding shares 51071390 (51.07 Million). Also see AZT total asset value for a full breakdown of the balance sheet.
Arcticzymes Technologies ASA Market Cap History: 2015 to 2026
Arcticzymes Technologies ASA's market capitalization history from 2015 to 2026. Data shows growth from $69.33 Million to $110.71 Million (4.16% CAGR). Also see AZT cash generation efficiency for how efficiently the company converts equity into cash flow.
Arcticzymes Technologies ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arcticzymes Technologies ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Arcticzymes Technologies ASA stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.98x
Arcticzymes Technologies ASA's market cap is 0.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
11.21x
Arcticzymes Technologies ASA's market cap is 11.21 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $60.73 Million | $71.90 Million | -$20.48 Million | 0.84x | N/A |
| 2017 | $36.01 Million | $66.69 Million | -$24.94 Million | 0.54x | N/A |
| 2018 | $18.92 Million | $66.77 Million | -$13.99 Million | 0.28x | N/A |
| 2019 | $25.53 Million | $77.25 Million | -$6.39 Million | 0.33x | N/A |
| 2020 | $341.80 Million | $93.45 Million | $83.12 Million | 3.66x | 4.11x |
| 2021 | $505.17 Million | $127.97 Million | $46.38 Million | 3.95x | 10.89x |
| 2022 | $385.06 Million | $136.97 Million | $32.86 Million | 2.81x | 11.72x |
| 2023 | $225.72 Million | $118.94 Million | $19.43 Million | 1.90x | 11.62x |
| 2024 | $71.69 Million | $104.35 Million | $8.47 Million | 0.69x | 8.47x |
| 2025 | $110.71 Million | $112.62 Million | $9.88 Million | 0.98x | 11.21x |
Competitor Companies of AZT by Market Capitalization
Companies near Arcticzymes Technologies ASA in the global market cap rankings as of September 17, 2026. Review AZT goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Arcticzymes Technologies ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Arcticzymes Technologies ASA Historical Marketcap From 2015 to 2026
Between 2015 and today, Arcticzymes Technologies ASA's market cap moved from $69.33 Million to $ 110.71 Million, with a yearly change of 4.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr110.71 Million | 0.00% |
| 2025 | Nkr110.71 Million | +54.42% |
| 2024 | Nkr71.69 Million | -68.24% |
| 2023 | Nkr225.72 Million | -41.38% |
| 2022 | Nkr385.06 Million | -23.78% |
| 2021 | Nkr505.17 Million | +47.80% |
| 2020 | Nkr341.80 Million | +1238.95% |
| 2019 | Nkr25.53 Million | +34.94% |
| 2018 | Nkr18.92 Million | -47.46% |
| 2017 | Nkr36.01 Million | -40.71% |
| 2016 | Nkr60.73 Million | -12.40% |
| 2015 | Nkr69.33 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Arcticzymes Technologies ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $110.71 Million USD |
| MoneyControl | $110.71 Million USD |
| MarketWatch | $110.71 Million USD |
| marketcap.company | $110.71 Million USD |
| Reuters | $110.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids… Read more